Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Czech Republic; Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University in Prague and General Teaching Hospital in Prague, Czech Republic.
Int J Med Inform. 2020 Sep;141:104205. doi: 10.1016/j.ijmedinf.2020.104205. Epub 2020 May 28.
The electronic prescribing system (EPS) is now widely used in the USA and largely also in EU member countries. Nevertheless, comparisons of different EPS are very scarce. Whilst the EU strives for cross-border interoperability in healthcare, the aim of this study is to provide a contemporary account of the state of national EPS in such countries.
For the sake of consistency the state of each of the EPS as of the end of 2018 was researched using an e-mail questionnaire. Respondents were chosen from among authors who have previously published studies on electronic prescriptions.
Data on EPS was gathered from 23 out of the 28 EU member states. In 2018 EPS was in daily use in 19 EU states, and one further country had a pilot project, whereas the remaining 3 were only at the planning stage. Most of the EPS do not differ significantly in basic design, however authentication procedures vary substantially.
There is a significant increase in EPS usage in EU countries as compared with previous studies. Cross-border interoperability in the EU is still limited, and further advancement might be hampered by differences in authentication procedures.
Although it was not possible to acquire data from all the EU countries, this study shows the present state of electronic prescription in most of them and demonstrates continuous development in this area.
电子处方系统（EPS）如今在美国得到了广泛应用，在欧盟成员国中也得到了广泛应用。然而，不同 EPS 之间的比较却非常少见。尽管欧盟致力于实现医疗保健领域的跨境互操作性，但本研究旨在提供这些国家目前国家 EPS 状况的最新描述。
为了保持一致性，我们使用电子邮件问卷研究了每个 EPS 在 2018 年底的状况。受访者是从之前发表过电子处方研究的作者中选择的。
从 28 个欧盟成员国中的 23 个收集了关于 EPS 的数据。2018 年，19 个欧盟国家日常使用 EPS，还有一个国家进行了试点项目，而其余 3 个国家仍处于规划阶段。大多数 EPS 在基本设计上没有显著差异，但认证程序差异很大。
与之前的研究相比，欧盟国家 EPS 的使用显著增加。欧盟的跨境互操作性仍然有限，认证程序的差异可能会阻碍进一步的发展。
尽管无法从所有欧盟国家获取数据，但本研究展示了大多数欧盟国家目前的电子处方状况，并展示了该领域的持续发展。
